Breast cancer drug with fewer side effects found to cut risk of tumors

Exemestane, sold under the brand name Aromasin, can reduce the risk of tumors by 65% among post-menopausal women prone to develop breast cancer, researchers say. It's already used to treat breast cancer and does not appear to have the potentially lethal side effects of tamoxifen or raloxifene. A drug already used to treat breast cancer can reduce the risk of tumors in high- and moderate-risk post-menopausal women by 65% over a three-year period, researchers reported Saturday.

Read the whole article on LA Times - Science

More from LA Times - Science